[Therapeutic program for ascites. Recommendations from the Swedish Society of Gastroenterology and Gastrointestinal Endoscopy].
As ascites is related to liver cirrhosis in 80% of the patients, the present therapeutic guidelines are focused on ascites in liver cirrhosis. A combination of spironolactone and furosemide is recommended as first line therapy in patients with mild to moderate ascites and is effective in 90% of patients. In patients with pronounced or tense ascites, first line treatment is total paracentesis with intravenous infusion of human albumin as colloid replacement. Maintenance therapy for the prevention of recurrent ascites is based on spironolactone with or without furosemide. The indications for peritoneovenous shunt, or transjugular intrahepatic stent-shunt (TIPSS), are limited and only recommended in strictly selected patients with refractory ascites. Ascites in liver cirrhosis is a symptom of advanced liver disease, and liver transplantation should always be considered in eligible patients.
Lööf
L
L
Centrum för klinisk forskning, centrallasarettet, Västerås. lars.loof@ltvastmanland.se
Prytz
H
H
Söderlund
C
C
Wallerstedt
S
S
D001201:Ascites / Q000188:drug therapy / Q000517:prevention & control / Q000628:therapy*; D000075202:Contraindications; D004232:Diuretics / Q000008:administration & dosage; D005665:Furosemide / Q000008:administration & dosage; D006801:Humans; D008103:Liver Cirrhosis / Q000188:drug therapy; D019152:Paracentesis / Q000379:methods; D010536:Peritoneovenous Shunt / Q000379:methods; D017410:Practice Guidelines as Topic; D012008:Recurrence; D012955:Societies, Medical; D013148:Spironolactone / Q000008:administration & dosage; D013548:Sweden
D004232:Diuretics; D013148:Spironolactone; D005665:Furosemide
Behandlingsprogram vid ascites. Rekommendationer från Svensk förening för gastroenterologi och gastrointestinal endoskopi.